American Association for Cancer Research
00085472can140749-sup-128193_1_supp_2573446_n934rx.docx (94.78 kB)

Supplementary Table 3 from PAD2 Overexpression in Transgenic Mice Promotes Spontaneous Skin Neoplasia

Download (94.78 kB)
journal contribution
posted on 2023-03-30, 23:03 authored by John L. McElwee, Sunish Mohanan, Sachi Horibata, Kelly L. Sams, Lynne J. Anguish, Dalton McLean, Iva Cvitaš, Joseph J. Wakshlag, Scott A. Coonrod

Supplementary Table 3: Primers for human quantitative RT-PCR (SYBR)



Peptidylarginine deiminase 2 (PAD2/PADI2) has been implicated in various inflammatory diseases and, more recently, cancer. The goal of this study was to test the hypothesis that PAD2 promotes oncogenesis using a transgenic mouse model. We found that about 37% of transgenic mice overexpressing human FLAG-PAD2 downstream of the MMTV-LTR promoter develop spontaneous neoplastic skin lesions. Molecular and histopathologic analyses of the resulting lesions find that they contain increased levels of markers for invasion, inflammation, and epithelial-to-mesenchymal transition (EMT) and that a subset of the lesions progress to invasive squamous cell carcinoma (SCC). We then stably overexpressed FLAG-PAD2 in the human SCC cell line, A431, and found that the PAD2-overexpressing cells were more tumorigenic in vitro and also contained elevated levels of markers for inflammation and EMT. Collectively, these studies provide the first genetic evidence that PAD2 functions as an oncogene and suggest that PAD2 may promote tumor progression by enhancing inflammation within the tumor microenvironment. Cancer Res; 74(21); 6306–17. ©2014 AACR.